Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Tislelizumab Combined With Induction Chemoradiotherapy and Subsequent Conversion Surgery for Locally Advanced Unresectable ESCC

NCT07039162 is registered in ClinicalTrials.gov with Ming-Yu Lien as lead sponsor.

NCT NCT07039162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07039162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Tislelizumab Combined With Induction Chemoradiotherapy and Subsequent Conversion Surgery for Locally Advanced Unresectable ESCC
Lead sponsor
Ming-Yu Lien
Phase
Phase 2
Overall status
Recruiting
Start date
September 26, 2025
Completion date
December 31, 2028
Enrollment
45 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal squamous cell carcinoma (escc), locally advanced unresectable esophageal cancer